| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Atazanavir Atovaquone 851 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential compromised antimalarial activity |
Not reported |
250 mg with 100 mg proguanil x 1 | Atovaquone AUC decreased 46%, Cmax decreased 49% |
Dose adjustment not established. If coadministering monitor for anti-malarial efficacy. |
| Efavirenz Atovaquone 475 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
250 mg with 100 mg proguanil x 1 | Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43% |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |
|
| Efavirenz Atovaquone 474 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
250 mg with 100 mg proguanil x 1 | Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43% |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |
|
| Efavirenz Atovaquone 473 | Orange: Minimal data to guide interaction | Consider using alternative agents | Potentially compromised antimalarial activity |
250 mg with 100 mg proguanil x 1 | Atovaquone AUC decreased 75%; Cmax decreased 44%. Proguanil AUC decreased 43% |
If coadministering,dose adjustment not established. Monitor for anti-malarial efficacy. |
